HCG

Bengaluru, India Founded: 1989 • Age: 37 yrs Listed Acquired By KKR
Chain of oncology hospitals
Request Access
Report Incorrect Data
Page last updated

About HCG

HCG is a publicly listed company based in Bengaluru (India) founded in 1989 by B S Ajai Kumar, and was acquired by KKR in December 2024. Chain of oncology hospitals. HCG has raised $36.59 million across 13 funding rounds from investors including IDFC First Bank, KKR and CVC. The company has 8,400 employees. HCG has completed 3 acquisitions, including Bangalore Assisted Conception Centre, Milann and Suchirayu Hospital. Its chief executive, as recorded, is Raj Gore. Its website hcgoncology.com draws about 87 thousand monthly visits. Its Indian entity Healthcare Global Enterprises Limited reported revenue of ₹2,572 Cr. Its focus areas include Hospital Chains, Single Specialty Hospital Chains and Oncology. Its competitors include CION Cancer Clinics, Cytecare and American Oncology Institute; 3 of its 3 listed competitors have raised funding.

Company details

HCG was established in 1989 in Bengaluru, India, as a chain of oncology hospitals focused on cancer care. Comprehensive services are delivered for diagnosis and treatment, encompassing chemotherapy, radiation therapy, surgical oncology, CAR T cell therapy, robotic surgery, liver transplantation, hematology, bone marrow transplantation, radiology, imaging, and immunotherapy. Operations span multiple facilities across the region in the healthcare sector.

  • Headquarters Bengaluru, India
  • Employees 8,400
  • Founders B S Ajai Kumar
  • Stage Acquired
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website hcgoncology.com
  • Social LinkedIn X Facebook Instagram YouTube
  • Acquired by KKR (Dec 2024)
  • Legal Name Healthcare Global Enterprises Ltd.
Operational Areas
Healthcare → Hospitals & Clinical Care
Key Metrics
  • Market Cap
    ₹8,221 Cr

    HCG · NSE

  • Share Price
    ₹549.65

    -0.18% today

  • Revenue
    ₹2,538 Cr

    FY 2025-26 · +14.4% YoY

  • EBITDA
    ₹414 Cr

    Margin 16.3%

  • Net Profit
    ₹38.32 Cr

    FY 2025-26 · -14.7% YoY

  • P/E (TTM)
    130.5x

    P/B 6.2x

  • ROE
    3.0%

    ROCE 7.2%

  • Debt / Equity
    1.58

    Interest cover 103.8x

  • Total Equity Funding
    $36.59M (USD)

    in 13 rounds

  • Latest Funding Round
    $86.18M (USD), Post-IPO

    Jun 2020

  • Investors
    IDFC First Bank

    & 6 more

  • Employee Count
    8,400
  • Investments & Acquisitions
    Bangalore Assisted Conception Centre

    & 2 more

  • Acquired by
    KKR

    (Dec 2024)

Apps and channels of HCG

its YouTube channel HCG Oncology has 4.53K subscribers and 30 videos.

HCG Oncology
YouTube 4.53K subscribers 30 videos Science & Technology
Open channel

Videos from HCG

The most watched videos on HCG's YouTube channel, HCG Oncology (4.53K subscribers). Click a video to play it here.

Life After Mouth Cancer Surgery | Dr. Nayan Gupta Explains What to Expect
82 views
Stage IV Prostate Cancer Warrior | Group Captain Vijay Hardas’ Inspiring Journey
66 views
A Brave Fight Against Cancer | Urbasi Nath’s Inspiring Recovery at HCG Cuttack
60 views
A Journey of Strength & Hope | Mrs. Radha’s Fight Against Stomach Cancer at HCG, Bangalore
48 views

More on HCG Oncology.

Funding Insights of HCG

HCG has successfully raised a total of $36.59M across 13 strategic funding rounds. The most recent funding activity was a Post-IPO round of $86.18 million completed in June 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $36.59M
  • Total Rounds 13
  • Last Round Post-IPO — $86.18M
  • First Round $938,303

    (Nov 2005)

  • Investors Count 6

Latest 10 of 13 funding rounds of HCG with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jun 2020$86.18MPost-IPO––
CVC
Mar 2013$24MSeries C––
Temasek
Jun 2011$12.59MSeries C––
–
Sep 2010$1.86MUnspecified––
–
Feb 2010$6.8MUnspecified–Milestone Religare Investments
–
Apr 2008$20MUnspecified––
Premji Invest
Aug 2007$6.93MUnspecified––
–
Jun 2007Unspecified––
InvAscent
Mar 2007$5.34MUnspecified––
–
Feb 2007$305,276Unspecified––
–
Valuation history

7 investors in total: 7 institutional.

Investors in HCG

HCG has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include IDFC First Bank, KKR and CVC.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
CVC
Mezzanine financing and equity investments are provided by CVC.
1981cvc.comNew York, United States
Temasek
An investment platform is provided for diverse sectors and geographies.
1974temasek.com.sgSingapore, Singapore
Premji Invest
Provides venture capital for technology startups and enterprise innovations worldwide.
premjiinvest.comBengaluru, India
InvAscent
Private equity firm focused on life sciences investments in India.
2005invascent.com
KKR
Multiple sectors are invested in by this private equity firm.
1976kkr.comNew York, United States
Milestone Religare Investments
Investment advisory firm
2007milestonereligare.comMumbai, India
IDFC First Bank
Commercial bank
1997idfcfirstbank.comMumbai, India
Premium access

Investor details for HCG

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Healthcare Global Enterprises Limited (HCG)

Healthcare Global Enterprises Limited is the primary company behind HCG. The boards of the 2 registered companies of HCG currently have 12 directors; the longest-serving is Basavalinga Ajaikumar Sadasivaiah, appointed in 2006. 38 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Basavalinga Ajaikumar Sadasivaiah
DIN 00713779
Director14 Jul 200620 yrs 3 moHealthcare Global Enterprises Limited
Bharatsinh Shivdan Gadhavi
DIN 01665633
Designated Partner22 Sep 20179 yrs 1 moHcg Rajkot Hospitals Llp
Anjali Rossi Ajaikumar
DIN 08057112
Director01 Apr 20215 yrs 6 moHealthcare Global Enterprises Limited
Geeta Mathur
DIN 02139552
Director17 Jun 20215 yrs 4 moHealthcare Global Enterprises Limited
Rajagopalan Raghavan
DIN 03627923
Director12 Aug 20215 yrs 2 moHealthcare Global Enterprises Limited
Ramesh S Bilimagga
DIN 00518434
Designated Partner01 Oct 20215 yrsHcg Rajkot Hospitals Llp
Pradip Manilal Kanakia
DIN 00770347
Director10 Feb 20224 yrs 8 moHealthcare Global Enterprises Limited
Rajiv Maliwal
DIN 00869035
Director25 May 20233 yrs 4 moHealthcare Global Enterprises Limited
Akshay Tanna
DIN 02967021
Director30 May 20251 yr 4 moHealthcare Global Enterprises Limited
Simrun Mehta
DIN 09118938
Director30 May 20251 yr 4 moHealthcare Global Enterprises Limited
Manish Mattoo
DIN 08431924
Whole-time director30 Jun 20251 yr 3 moHealthcare Global Enterprises Limited
Bijou Kurien
DIN 01802995
Director30 Jun 20251 yr 3 moHealthcare Global Enterprises Limited

People of HCG

57 people are tracked at HCG (30 in leadership, 27 in team); the tracked headcount is 8,400.

NameRoleGroup
B S Ajai Kumar
Co-Founder & CSRLeadership
Raj Gore
CEOLeadership
Roshan A
Senior General Manager ITLeadership
Pooja Prajapati
Head Of OperationsLeadership
Deepti Gautam Tewari
Chief Human Resource OfficerLeadership
Madan Sampath
Chief Supply Chain OfficerLeadership
Ruby Ritolia
Chief Financial OfficerLeadership
Sudeep Dey
Chief Information OfficerLeadership
Mc Jayaprakash
Vice President Human ResourcesLeadership
Aswin Kumar
Associate Vice President - F & ALeadership
Vijay S Shanbhag
Head- Internal Audit And Risk ManagementLeadership
Arbind Kumar Verma
Unit Head Finance And AccountingLeadership
Lokesh L
IT HeadLeadership
Aman Singh Ahluwalia
Chief Operating Officer At HCG (healthcare Global) Manavata Cancer HospitalsLeadership
Dr. Ajay Singh
Chief Operating OfficerLeadership
Dr Durga Prasad
Head Of OperationsLeadership
Manisha Kumar
Regional Chief Operating OfficerLeadership
George Alex
Regional Business Head - MH & MPLeadership
Nitin Bamaniya
Chief Operating OfficerLeadership
Kiran Kumar Maddula
Regional Head - Sales & MarketingLeadership

37 more people are available in the full profile.

Premium access

Complete people profiles for HCG

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of HCG

HCG is a publicly listed company on the NSE with ticker symbol HCG in India, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date30 Mar 2016
  • Listed onBSE: 539787 · NSE: HCG
  • Listed entityHealthCare Global Enterprises Ltd.
  • Exchange sectorHealth services
  • ISININE075I01017
  • Share price₹586.95 (+1.31% on the day) · 2026-10-14
  • Market capitalisation₹8,647 Cr
  • Price to earnings376.1
  • EPS (diluted, trailing year)₹1.56
  • Volume (last session)99,673

Financials of HCG

Exchange-reported figures of Healthcare Global Enterprises Limited, the listed company behind HCG (NSE: HCG).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹2,538 Cr
+14.4% YoY
EBITDA
₹414 Cr
+8.3% YoY
Profit After Tax
₹38.32 Cr
-14.7% YoY
Net Worth
₹1,332 Cr
+44.4% YoY
Total Assets
₹3,279 Cr
+11.1% YoY
Total Debt
₹1,735 Cr
-5.5% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2,5382,2181,9081,6911,3951,0091,092
Revenue growth+14.4%+16.3%+12.8%+21.3%+38.2%-7.6%-
EBITDA41438332529617822.73157
EBITDA margin+16.3%+17.3%+17.1%+17.5%+12.8%+2.3%+14.3%
Profit before tax26.9156.9667.7144.8787.76(229)(119)
Net profit38.3244.9447.0829.868.60(102)(107)
Net profit margin+1.5%+2.0%+2.5%+1.8%+0.6%-10.1%-9.8%
EPS (₹)0.923.193.462.113.87(15.43)(12.03)
Balance sheet
Total assets3,2792,9512,1881,8201,8341,7281,878
Net worth1,332922826861870697381
Total debt1,7351,8371,2749019159771,347
Cash & bank54134830319719840.8532.02
Net working capital49425516696.42118132(64.17)
Cash flow
Cash from operations347317285252220121130
Cash from investing(177)(488)(226)(133)125(171)(101)
Cash from financing241(42.44)(64.02)(140)(155)112(58.43)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue695652633647613585559554
Revenue growth (YoY)+13.4%+11.5%+13.3%+16.9%+16.7%---
Other income13.0613.592.472.937.5110.235.5411.13
EBITDA12293.1796.8912310810688.38102
EBITDA margin+17.6%+14.3%+15.4%+19.1%+17.6%+18.1%+15.9%+18.5%
Depreciation70.4262.8160.6562.8057.9158.0756.5249.74
Interest39.8742.7044.7843.6245.4744.1740.7035.98
Profit before tax25.031.25(6.07)19.8211.9213.62(3.30)27.65
Tax8.57(2.79)1.83(0.84)5.946.85(11.05)6.97
Net profit16.464.04(7.90)20.665.986.777.7520.68
EPS (₹)0.920.15(0.68)1.160.340.520.491.28
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,3591,2771,1711,006850609688
Revenue growth+6.5%+9.0%+16.4%+18.3%+39.6%-11.6%-
EBITDA18017718117470.35(85.41)84.83
EBITDA margin+13.3%+13.8%+15.4%+17.3%+8.3%-14.0%+12.3%
Profit before tax9.6119.5853.7057.6281.03(205)(65.46)
Net profit65.7817.6941.1543.1113.30(38.39)(22.47)
Net profit margin+4.8%+1.4%+3.5%+4.3%+1.6%-6.3%-3.3%
EPS (₹)0.980.252.352.892.75(15.28)(6.01)
Balance sheet
Total assets2,6852,3661,9811,5341,4781,4371,476
Net worth1,6051,1911,1811,1451,098924615
Total debt1,0221,118758347349481827
Cash & bank47426423780.3712014.4615.14
Net working capital650408281187190190(52.39)
Cash flow
Cash from operations16014620913012470.8986.34
Cash from investing(75.82)(347)(254)(138)48.65(246)(116)
Cash from financing336(41.55)95.92(41.71)(41.04)236(2.76)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue377350342346327324313329
Revenue growth (YoY)+15.2%+8.0%+9.5%+5.0%+11.4%---
Other income9.5614.922.993.827.949.465.299.79
Total expenses317323296284277265305268
EBITDA59.2227.6246.4462.3049.8558.897.5061.58
EBITDA margin+15.8%+7.9%+13.6%+18.1%+15.3%+18.2%+2.4%+18.7%
Depreciation39.5731.3030.0930.1628.2529.0527.9027.88
Interest21.7320.1920.6121.3624.3022.5021.2720.58
Profit before tax7.48(8.95)(1.27)14.605.2416.80(36.38)22.91
Tax1.90(10.48)(0.09)3.821.796.650.954.96

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 23 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue695652633647613585559554
Revenue growth (YoY)+13.4%+11.5%+13.3%+16.9%+16.7%---
Other income13.0613.592.472.937.5110.235.5411.13
EBITDA12293.1796.8912310810688.38102
EBITDA margin+17.6%+14.3%+15.4%+19.1%+17.6%+18.1%+15.9%+18.5%
Depreciation70.4262.8160.6562.8057.9158.0756.5249.74
Interest39.8742.7044.7843.6245.4744.1740.7035.98
Profit before tax25.031.25(6.07)19.8211.9213.62(3.30)27.65
Tax8.57(2.79)1.83(0.84)5.946.85(11.05)6.97
Net profit16.464.04(7.90)20.665.986.777.7520.68
EPS (₹)0.920.15(0.68)1.160.340.520.491.28
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2,5382,2181,9081,6911,3951,0091,092
Revenue growth+14.4%+16.3%+12.8%+21.3%+38.2%-7.6%-
Other income33.4340.3025.4816.2216626.9810.27
Total expenses2,1241,8361,5831,3961,217986936
Employee cost379353308275234196208
EBITDA41438332529617822.73157
EBITDA margin+16.3%+17.3%+17.1%+17.5%+12.8%+2.3%+14.3%
Depreciation244211174163158159148
Interest17715510910497.77119138
Profit before tax26.9156.9667.7144.8787.76(229)(119)
Tax4.148.1326.4027.2548.85(7.56)6.19
Net profit38.3244.9447.0829.868.60(102)(107)
Net profit margin+1.5%+2.0%+2.5%+1.8%+0.6%-10.1%-9.8%
EPS (₹)0.923.193.462.113.87(15.43)(12.03)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital14913913913913912588.69
Reserves & surplus1,183783686721731528293
Shareholders' funds (net worth)1,332922826861870697381
Minority interest78.2467.6139.348.8913.4316.8238.51
Secured loans879962639376371421688
Unsecured loans856875636525544556658
Total debt1,7351,8371,2749019159771,347
Total liabilities3,2792,9512,1881,8201,8341,7281,878
Assets
Gross block3,8023,6162,7812,4192,2551,9332,025
Net block2,4622,4421,7581,5531,5471,3821,646
Capital work in progress18.5724.7683.1818.1821.7330.0146.09
Investments13.8811.3110.339.698.8226.2834.12
Inventories59.8253.0242.6738.2929.9721.1123.26
Sundry debtors421401294303217187186
Cash & bank balances54134830319719840.8532.02
Loans & advances11442.1840.0842.9057.4118662.85
Total current assets1,135844680580502435304
Total current liabilities641589513484384303368
Net working capital49425516696.42118132(64.17)
Total assets3,2792,9512,1881,8201,8341,7281,878
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash(47.06)1661711932.87(58.79)(29.12)
Net cash from operating activities347317285252220121130
Net cash from investing activities(177)(488)(226)(133)125(171)(101)
Net cash from financing activities241(42.44)(64.02)(140)(155)112(58.43)
Net change in cash410(213)(5.16)(21.51)19061.66(29.67)
Closing cash54134830319719840.8532.02
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+14.4%+16.3%+12.8%+21.3%+38.2%-7.6%-
EBITDA growth+8.3%+17.6%+10.1%+65.9%+684.1%-85.5%-
PBT growth-52.8%-15.9%+50.9%-48.9%+9998.0%-91.8%-257.2%
Net income growth-14.7%-4.6%+57.7%+247.2%+108.4%+4.5%-
Revenue CAGR (3Y)+14.5%+16.7%+23.7%+15.7%+12.6%+6.8%+16.0%
EBITDA CAGR (3Y)+11.9%+29.0%+142.8%+23.6%+16.9%-40.5%+14.3%
Profitability & leverage
Net income margin+0.9%+2.2%+2.2%+1.0%+2.8%-21.9%-11.5%
Return on capital employed+7.2%+7.1%+7.2%+6.6%+4.6%0.0%0.0%
Return on net worth+3.1%+3.7%+3.1%+1.4%-0.6%0.0%0.0%
Debt / equity1.581.781.291.051.212.162.34
Long-term debt / equity1.211.391.100.951.051.811.93
Interest cover103.8390.2772.0378.32490.08-87.311,695.20
Efficiency & per share
Fixed asset turnover0.680.690.730.720.670.510.68
Inventory turnover44.9946.3647.1349.5654.6145.4943.67
Debtors turnover6.186.386.406.516.905.426.38
EPS (₹)0.923.193.462.113.87(15.43)(12.03)
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)89.2166.1659.2861.8662.6152.1142.99
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue377350342346327324313329
Revenue growth (YoY)+15.2%+8.0%+9.5%+5.0%+11.4%---
Other income9.5614.922.993.827.949.465.299.79
Total expenses317323296284277265305268
EBITDA59.2227.6246.4462.3049.8558.897.5061.58
EBITDA margin+15.8%+7.9%+13.6%+18.1%+15.3%+18.2%+2.4%+18.7%
Depreciation39.5731.3030.0930.1628.2529.0527.9027.88
Interest21.7320.1920.6121.3624.3022.5021.2720.58
Profit before tax7.48(8.95)(1.27)14.605.2416.80(36.38)22.91
Tax1.90(10.48)(0.09)3.821.796.650.954.96
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,3591,2771,1711,006850609688
Revenue growth+6.5%+9.0%+16.4%+18.3%+39.6%-11.6%-
Other income35.6038.5820.1014.5514229.7912.11
Total expenses1,1791,100990832779694604
Employee cost212221205175157137143
EBITDA18017718117470.35(85.41)84.83
EBITDA margin+13.3%+13.8%+15.4%+17.3%+8.3%-14.0%+12.3%
Depreciation12011196.9288.9788.3686.5879.41
Interest86.4684.1450.0741.4942.8062.8682.99
Profit before tax9.6119.5853.7057.6281.03(205)(65.46)
Tax(4.96)16.0520.9017.4342.79(13.51)(12.16)
Net profit65.7817.6941.1543.1113.30(38.39)(22.47)
Net profit margin+4.8%+1.4%+3.5%+4.3%+1.6%-6.3%-3.3%
EPS (₹)0.980.252.352.892.75(15.28)(6.01)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital14913913913913912588.69
Reserves & surplus1,4551,0521,0421,006959755526
Shareholders' funds (net worth)1,6051,1911,1811,1451,098924615
Secured loans54762239711283.42204398
Unsecured loans475495361235266278429
Total debt1,0221,118758347349481827
Total liabilities2,6852,3661,9811,5341,4781,4371,476
Assets
Gross block1,9041,6991,5661,2751,1771,0581,141
Net block1,1221,038974788774745914
Capital work in progress13.7922.6136.499.224.8227.6143.61
Investments704696506475439366316
Inventories25.2419.7623.2221.2217.3011.9512.51
Sundry debtors262262221212160147152
Cash & bank balances47426423780.3712014.4615.14
Loans & advances12094.5750.4558.5658.6515460.62
Total current assets882640532373356328241
Total current liabilities232232250186166138293
Net working capital650408281187190190(52.39)
Total assets2,6852,3661,9811,5341,4781,4371,476
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash(122)12170.31119(12.68)(73.86)(41.45)
Net cash from operating activities16014620913012470.8986.34
Net cash from investing activities(75.82)(347)(254)(138)48.65(246)(116)
Net cash from financing activities336(41.55)95.92(41.71)(41.04)236(2.76)
Net change in cash421(243)50.87(49.02)13261.19(32.41)
Closing cash47426423780.3712014.4615.14
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+6.5%+9.0%+16.4%+18.3%+39.6%-11.6%-
EBITDA growth+2.1%-2.3%+4.1%+146.7%+182.4%-200.7%-
PBT growth-50.9%-63.5%-6.8%-28.9%+9998.0%-213.3%-
Net income growth+271.9%-57.0%-4.6%+224.1%+134.6%-70.9%-
Revenue CAGR (3Y)+10.6%+14.5%+24.4%+13.5%+9.9%+1.3%+8.1%
EBITDA CAGR (3Y)+1.3%+35.9%-+26.9%-9.2%-+0.9%
Profitability & leverage
Net income margin+1.1%+0.3%+2.8%+4.0%+4.5%-31.5%-7.7%
Return on capital employed+5.7%+6.0%+6.3%+5.9%+4.6%0.0%0.0%
Return on net worth+4.3%+1.3%+3.1%+3.1%+1.2%0.0%0.0%
Debt / equity0.770.790.480.310.410.850.99
Long-term debt / equity0.520.560.390.270.330.660.79
Interest cover142.98129.1759.8449.07-237.65-36.551,531.18
Efficiency & per share
Fixed asset turnover0.750.780.820.820.760.550.75
Inventory turnover60.4259.4052.6852.2158.1149.7847.72
Debtors turnover5.195.295.415.405.524.064.62
EPS (₹)0.980.252.352.892.75(15.28)(6.01)
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)107.4985.4584.8282.3178.9670.1969.29

Investments & Acquisitions by HCG

HCG has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Bangalore Assisted Conception Centre, Milann and Suchirayu Hospital.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Suchirayu Hospital
Multispecialty hospital services are delivered in Hubli, India.
suchirayuhospital.comHubli, India2019Nov 2021$4.43M
Milann
Milann is recognized as a leading fertility and IVF center in India.
milann.co.inBengaluru, India1990May 2013••••
Bangalore Assisted Conception Centre
A chain of fertility clinics is operated in Bengaluru.
baccweb.comBengaluru, India1990Mar 2013••••
Premium access

Complete acquisition details for HCG

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of HCG

8 dated milestones of HCG across 35 years, from founding to its latest funding, stage changes and deals.

  1. Founded HCG is founded.
  2. Funding First funding round of $938K.
  3. Acquisition Acquires Bangalore Assisted Conception Centre.
  4. Acquisition Acquires Milann.
  5. IPO Lists on the stock exchange (IPO).
  6. Funding Latest funding round, Post-IPO, of $86.2M.
  7. Acquisition Acquires Suchirayu Hospital.
  8. Exit Acquired by KKR.

Competitors of HCG

HCG has 3 listed competitors in our database, 3 of them funded. They include CION Cancer Clinics, Cytecare and American Oncology Institute.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
CION Cancer Clinics
cioncancerclinics.com2019Hyderabad, India$10.87M119
Cancer treatments and support are provided by a clinic chain.
Cytecare
cytecare.com2014Bengaluru, India$78.45M264
Oncology hospitals chain offering specialized cancer treatments.
American Oncology Institute
americanoncology.com2006Hyderabad, India$4.19M1,231
Cancer care is provided through a chain of specialized hospitals.
Premium access

Detailed competitors of HCG

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of HCG

The website of HCG (hcgoncology.com) receives about 86.8K visits a month.

  • Monthly visits
    86.8K

    ▲ 2.7% vs previous month

Similar websites

Websites whose visitors overlap most with HCG. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
HCG Hospitals
hcghospitals.in
100%
27.3K#857,509View details
healthcareglobal.com
healthcareglobal.com
95%
–
Nanavati Hospital
nanavatihospital.org
87%
View details
Medfin
medfin.in
83%
71.8K#582,617View details
Fortis Healthcare
fortishealthcare.com
81%
808.8K#56,407View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 40 similar websites and full traffic analytics for HCG

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 40 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Hospitals & Clinical Care

3 companies that operate in the same segment as HCG (Hospitals & Clinical Care) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Cloudnine
Maternity, childcare, and fertility services are delivered via hospital chains.
2007Bengaluru, Karnataka, IndiaUSD 204.87 MUSD 140.46 M4,459
Medanta
Chain of multi-super specialty healthcare hospitals
2004Gurugram, Haryana, IndiaUSD 104.7 MUSD 461.72 M12,240
KIMS Hospitals
Multispeciality secondary and tertiary care is provided by hospital chains.
1999Secunderabad, Telangana, IndiaUSD 62.46 MUSD 416.2 M6,490
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Hcg

Buy HealthCare Global Enterprises; target of Rs 820: Prabhudas Lilladher
Moneycontrol • 18 days ago
HCG Aastha Cancer Centre Launches Advanced PET-CT, Gamma Camera, and Targeted Therapies
The Tribune • 24 days ago
Medicover India hospitals to be profitable in 18 months, eyes 20-25% margins
Reuters • 1 month ago
HCG CEO Manish Mattoo sees margin expansion, acquisitions driving next leg of growth
Moneycontrol • 2 months ago
Buy HealthCare Global Enterprises; target of Rs 800: ICICI Securities
Moneycontrol • 2 months ago
Buy HealthCare Global Enterprises; target of Rs 820: Prabhudas Lilladher
Moneycontrol • 2 months ago
HCG: Revenue up 13% YoY, adjusted EBITDA margin at 19.4%, with strong growth and margin expansion
Quartr • 2 months ago
HCG: Revenue and net profit rose year-over-year, with key divestment and acquisition completed
Quartr • 2 months ago
HCG: Q1 FY27 saw 13% revenue growth, 20% higher adjusted EBITDA, and 190% PAT surge, driven by oncology focus
Quartr • 2 months ago
Healthcare Global Enterprises Limited June-Quarter Consol Net Profit 137.7 Million Rupees
Reuters • 2 months ago
Premium access

Complete news archive for HCG

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about HCG

HCG was founded in 1989 and raised its 1st funding round 16 years after it was founded.

HCG is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.

Raj Gore is the CEO of HCG, as recorded in our data.

HCG is a funded company, having raised a total of $36.59M across 13 funding rounds to date. The company's 1st funding round was a Unspecified of $305.28K, raised on Nov 2005.

HCG has 8,400 employees.

The primary company behind HCG, Healthcare Global Enterprises Limited, reported revenue of ₹2,572 Cr for FY 2026, up 14% year on year.

HCG was established in 1989 in Bengaluru, India, as a chain of oncology hospitals focused on cancer care. Comprehensive services are delivered for diagnosis and treatment, encompassing chemotherapy, radiation therapy, surgical oncology, CAR T cell therapy, robotic surgery, liver transplantation, hematology, bone marrow transplantation, radiology, imaging, and immunotherapy. Operations span multiple facilities across the region in the healthcare sector.

HCG's top competitors include Cytecare, CION Cancer Clinics and American Oncology Institute.

Yes, HCG is publicly traded on NSE under the ticker symbol HCG.

HCG has made 3 acquisitions, including Bangalore Assisted Conception Centre, Milann, and Suchirayu Hospital.

HCG has 7 investors. Key investors include IDFC First Bank, KKR, CVC, Temasek, and Premji Invest.

HCG is associated with 2 legal entities: Healthcare Global Enterprises Limited, Hcg Rajkot Hospitals Llp.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available